Future of nonnucleoside reverse transcriptase inhibitors.
作者信息
Sluis-Cremer Nicolas
机构信息
Department of Medicine, Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261
出版信息
Proc Natl Acad Sci U S A. 2018 Jan 23;115(4):637-638. doi: 10.1073/pnas.1720975115. Epub 2018 Jan 11.
Abstract
摘要
相似文献
1
Future of nonnucleoside reverse transcriptase inhibitors.非核苷类逆转录酶抑制剂的未来
Proc Natl Acad Sci U S A. 2018 Jan 23;115(4):637-638. doi: 10.1073/pnas.1720975115. Epub 2018 Jan 11.
2
Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial.TMC278 在初治 HIV-1 感染者中的疗效和安全性：一项 IIb 期随机试验的第 96 周结果。
AIDS. 2010 Jan 2;24(1):55-65. doi: 10.1097/QAD.0b013e32833032ed.
3
Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.在随机的ANRS 121试验中，与非核苷类逆转录酶抑制剂或蛋白酶抑制剂+核苷类逆转录酶抑制剂相比，无核苷类逆转录酶抑制剂方案（非核苷类逆转录酶抑制剂+蛋白酶抑制剂）更易出现耐药。
AIDS. 2009 Jul 31;23(12):1605-8. doi: 10.1097/QAD.0b013e32832d9031.
4
Is there a role for etravirine in patients with Nonnucleoside reverse transcriptase inhibitor resistance?依曲韦林在非核苷类逆转录酶抑制剂耐药患者中是否有作用？
AIDS. 2008 May 11;22(8):989-90. doi: 10.1097/QAD.0b013e3282fa75df.
5
The HEPT Analogue WPR-6 Is Active against a Broad Spectrum of Nonnucleoside Reverse Transcriptase Drug-Resistant HIV-1 Strains of Different Serotypes.庚烷类似物WPR-6对不同血清型的多种非核苷类逆转录酶耐药HIV-1毒株具有活性。
Antimicrob Agents Chemother. 2015 Aug;59(8):4882-8. doi: 10.1128/AAC.00440-15. Epub 2015 Jun 8.
6
High rate multiple drug resistances in HIV-infected patients failing nonnucleoside reverse transcriptase inhibitor regimens in Thailand, where subtype A/E is predominant.在泰国，A/E亚型为主的地区，接受非核苷类逆转录酶抑制剂治疗方案失败的HIV感染患者中出现高比例多重耐药情况。
J Int Assoc Physicians AIDS Care (Chic). 2006 Dec;5(4):152-6. doi: 10.1177/1545109706294288.
7
Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.在1型人类免疫缺陷病毒逆转录酶中选择核苷类抑制剂耐药性突变的新型非核苷类抑制剂。
Antimicrob Agents Chemother. 2006 Aug;50(8):2772-81. doi: 10.1128/AAC.00127-06.
8
Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to nonnucleoside analogues.耐药突变对既往非核苷类类似物治疗失败的HIV患者依曲韦林敏感性的表型影响。
AIDS. 2008 Nov 12;22(17):2395-8. doi: 10.1097/QAD.0b013e32831692fb.
9
10
Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort.HIV-1逆转录酶中的突变可能与对非核苷类逆转录酶抑制剂高度敏感相关：对城市观察队列中基于依非韦伦治疗反应的影响
J Infect Dis. 2004 May 1;189(9):1688-95. doi: 10.1086/382960. Epub 2004 Apr 13.
引用本文的文献
1
Development of enhanced HIV-1 non-nucleoside reverse transcriptase inhibitors with improved resistance and pharmacokinetic profiles.开发具有改善的耐药性和药代动力学特征的增强型HIV-1非核苷类逆转录酶抑制剂。
Sci Adv. 2025 May 30;11(22):eadt8916. doi: 10.1126/sciadv.adt8916.
2
The cumulative prevalence of HIV-1 drug resistance in perinatal HIV.围产期感染艾滋病毒中HIV-1耐药性的累积患病率。
AIDS. 2025 Jul 15;39(9):1161-1177. doi: 10.1097/QAD.0000000000004202. Epub 2025 Apr 15.
3
Antivirals for Broader Coverage against Human Coronaviruses.用于更广泛覆盖人类冠状病毒的抗病毒药物。
Viruses. 2024 Jan 20;16(1):156. doi: 10.3390/v16010156.
4
Direct and indirect cardiovascular and cardiometabolic sequelae of the combined anti-retroviral therapy on people living with HIV.联合抗逆转录病毒疗法对艾滋病毒感染者的直接和间接心血管及心脏代谢后遗症
Front Physiol. 2023 Mar 27;14:1118653. doi: 10.3389/fphys.2023.1118653. eCollection 2023.
5
Antiviral Drug Discovery for the Treatment of COVID-19 Infections.抗新冠病毒药物研发用于治疗 COVID-19 感染。
Viruses. 2022 May 4;14(5):961. doi: 10.3390/v14050961.
6
HIV-1 Reverse Transcriptase Inhibition by Major Compounds in a Kenyan Multi-Herbal Composition (CareVid™): In Vitro and In Silico Contrast.肯尼亚多草药组合物（CareVid™）中主要化合物对HIV-1逆转录酶的抑制作用：体外和计算机模拟对比
Pharmaceuticals (Basel). 2021 Sep 30;14(10):1009. doi: 10.3390/ph14101009.
7
The development of an effective synthetic route of rilpivirine.利匹韦林有效合成路线的开发。
BMC Chem. 2021 Apr 1;15(1):22. doi: 10.1186/s13065-021-00749-y.
8
The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.HIV-1 非核苷类逆转录酶抑制剂（NNRTIs）从实验室到临床的历程。
J Med Chem. 2019 May 23;62(10):4851-4883. doi: 10.1021/acs.jmedchem.8b00843. Epub 2018 Dec 27.
本文引用的文献
1
From in silico hit to long-acting late-stage preclinical candidate to combat HIV-1 infection.从计算机筛选到长效晚期临床前候选药物，抗击 HIV-1 感染。
Proc Natl Acad Sci U S A. 2018 Jan 23;115(4):E802-E811. doi: 10.1073/pnas.1717932115. Epub 2017 Dec 26.
2
Structural and Preclinical Studies of Computationally Designed Non-Nucleoside Reverse Transcriptase Inhibitors for Treating HIV infection.用于治疗HIV感染的计算机辅助设计非核苷类逆转录酶抑制剂的结构及临床前研究
Mol Pharmacol. 2017 Apr;91(4):383-391. doi: 10.1124/mol.116.107755. Epub 2017 Feb 6.
3
Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women.双汰芝阴道环预防女性艾滋病的安全性和有效性。
N Engl J Med. 2016 Dec 1;375(22):2133-2143. doi: 10.1056/NEJMoa1602046.
4
Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment.长效利匹韦林作为 HIV-1 预防的潜在暴露前预防（MWRI-01 研究）：一项开放性、1 期、房室、药代动力学和药效学评估。
Lancet HIV. 2016 Dec;3(12):e569-e578. doi: 10.1016/S2352-3018(16)30113-8. Epub 2016 Sep 16.
5
First-in-Human Trial of MIV-150 and Zinc Acetate Coformulated in a Carrageenan Gel: Safety, Pharmacokinetics, Acceptability, Adherence, and Pharmacodynamics.卡拉胶凝胶共配制的MIV-150与醋酸锌的首次人体试验：安全性、药代动力学、可接受性、依从性和药效学。
J Acquir Immune Defic Syndr. 2016 Dec 15;73(5):489-496. doi: 10.1097/QAI.0000000000001136.
6
Distinct Pharmacodynamic Activity of Rilpivirine in Ectocervical and Colonic Explant Tissue.利匹韦林在外阴宫颈和结肠外植体组织中的独特药效学活性。
Antimicrob Agents Chemother. 2016 Apr 22;60(5):2765-70. doi: 10.1128/AAC.00167-16. Print 2016 May.
7
Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women.使用含达匹韦林的阴道环预防女性感染HIV-1。
N Engl J Med. 2016 Dec 1;375(22):2121-2132. doi: 10.1056/NEJMoa1506110. Epub 2016 Feb 22.
8
A randomized, double-blind, placebo-controlled, short-term monotherapy study of doravirine in treatment-naive HIV-infected individuals.多韦拉韦在初治HIV感染个体中的随机、双盲、安慰剂对照短期单药治疗研究。
AIDS. 2016 Jan 2;30(1):57-63. doi: 10.1097/QAD.0000000000000876.
9
Long-acting rilpivirine for HIV prevention.用于艾滋病预防的长效利匹韦林
Curr Opin HIV AIDS. 2015 Jul;10(4):253-7. doi: 10.1097/COH.0000000000000160.
10
Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis.传播的HIV-1耐药性的分子流行病学和遗传机制的地理及时间趋势：一项个体患者和序列水平的荟萃分析。
PLoS Med. 2015 Apr 7;12(4):e1001810. doi: 10.1371/journal.pmed.1001810. eCollection 2015 Apr.
Zotero 插件